|
[Related PubMed/MEDLINE]
Total Number of Papers: 762
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2022 |
Adherence, Efficacy, and Safety of Wearable Technology-Assisted Combined Home-Based Exercise in Chinese Patients With Ankylosing Spondylitis: Randomized Pilot Controlled Clinical Trial. |
AS, ASDAS, BASFI, BASMI, PGA, PhGA |
| 2 |
2022 |
Anti-TNF treatment in ankylosing spondylitis patients with chronic kidney disease: Is it effective and safe? |
AS, GFR, TNF |
| 3 |
2022 |
Central Obesity in Axial Spondyloarthritis: The Missing Link to Understanding Worse Outcomes in Women? |
ASQoL, axSpA, BASFI, HAQ, WHR |
| 4 |
2022 |
Comparison of ankylosing spondylitis patients with and without fibromyalgia syndrome according to the disease activation scores and response to treatment. |
AS, ASDAS, CRP, ESR, FM, HLA-B27 |
| 5 |
2022 |
Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA. |
ADA, ASDAS, axSpA, BASFI, EQ-5D, HAQ, OR, PROs, SF-36, TNF |
| 6 |
2022 |
Disease Activity-Guided Stepwise Tapering but Not Discontinuation of Biologics Is a Feasible Therapeutic Strategy for Patients with Ankylosing Spondylitis: Real-World Evidence. |
AS, ASDAS-CRP, BASFI, ETN, LDA, PtGA |
| 7 |
2022 |
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. |
AS, HRQoL, PROs, SF-36v2, WPAI |
| 8 |
2022 |
Effect of Warming Yang, Tonifying Kidney, and Removing Arthralgia Therapy on Cold-Dampness Arthralgia Type Ankylosing Spondylitis and Its Influence on the Levels of Humoral Factor in Human Serum. |
AS, BASFI, BMP-2, CXCL16, DKK1, IL-17, SOST, TCM, TNF-alpha, VAS |
| 9 |
2022 |
Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study. |
ASDAS, axSpA, LDA, nr-axSpA, r-axSpA, SEC, VLDA |
| 10 |
2022 |
Efficacy of thunder-fire moxibustion in treating ankylosing spondylitis of kidney deficiency and governor meridian cold and its influence on TNF-α and RANKL: study protocol for a prospective, nonblinded, single-center, randomized controlled trial. |
AS, BASFI, RANKL, SF-36, TCM, TNF-alpha |
| 11 |
2022 |
Employment, Work Productivity, and Biologic Treatments in Self-Reported Axial Spondyloarthritis: a Cross-Sectional Study in a Female Predominant Population from the ArthritisPower Registry. |
axSpA, bDMARD, WPAI |
| 12 |
2022 |
Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France. |
ASDAS, axSpA, SEC |
| 13 |
2022 |
Intravoxel incoherent motion diffusion-weighted imaging as a quantitative tool for evaluating disease activity in patients with axial spondyloarthritis. |
ADC, axSpA, BASFI, IVIM-DWI, MRI, PGA, SIJ, SPARCC |
| 14 |
2022 |
Knockdown of circular RNA hsa_circ_0003307 inhibits synovial inflammation in ankylosing spondylitis by regulating the PI3K/AKT pathway. |
AS, BASFI, CRP, ELISA, ESR, FLS, HC, hsa, PBMCs, PI3K, qRT-PCR, TNF-alpha, TNFAIP2 |
| 15 |
2022 |
Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. |
ASDAS, CZP, nr-axSpA, OC, SFE, TEAE |
| 16 |
2022 |
Measuring quality of life of patients with axial spondyloarthritis for economic evaluation. |
ASDAS, axSpA, BASFI |
| 17 |
2022 |
Minimal Impact of the COVID-19 Pandemic on Disease Activity and Health-Related Quality of Life in Patients With Ankylosing Spondylitis Receiving Bimekizumab: Exploratory Analyses From a Phase 2b Open-Label Extension Study. |
AS, ASDAS-CRP, ASQoL, HRQoL, OLE |
| 18 |
2022 |
Monitoring of Disease Activity With a Smartphone App in Routine Clinical Care in Patients With Axial Spondyloarthritis. |
axSpA, PRO |
| 19 |
2022 |
Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis. |
ASDAS, axSpA, CRP, CV |
| 20 |
2022 |
Prevalence and risk factors for uveitis in spondyloarthritis. |
OR, SpA |
| 21 |
2022 |
Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis. |
AIDs, DMARDs, HC, SpA, YF |
| 22 |
2022 |
Protective Effect and Possible Mechanisms of Tripterygium Glycosides in Patients with Ankylosing Spondylitis: A Systematic Review and Meta-Analysis. |
ADR, AS, BASFI, CRP, ESR, RCTs, SP-VAS, TG |
| 23 |
2022 |
Radiomic Quantification for MRI Assessment of Sacroiliac Joints of Patients with Spondyloarthritis. |
BASFI, CRP, ESR, MASES, MRI, SpA, SPAIR, STIR |
| 24 |
2022 |
Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry. |
AS, ASDAS, bDMARDs, DAPSA, DAS28-CRP, IL-17A, PsA, SJC, TJC |
| 25 |
2022 |
Relationship between inflammation and radiographic progression in patients with ankylosing spondylitis attaining a BASDAI of <4 during TNF inhibitor treatment. |
AS, CRP, mSASSS, TNFi |
| 26 |
2022 |
Sustained low disease activity measured by ASDAS slow radiographic spinal progression in axial spondyloarthritis patients treated with TNF-inhibitors: data from REGISPONSERBIO. |
ASDAS, axSpA, CRP, mSASSS, REGISPONSERBIO, TNFi |
| 27 |
2022 |
The BASDAI Cut-Off for Disease Activity Corresponding to the ASDAS Scores in a Taiwanese Cohort of Ankylosing Spondylitis. |
AS, ASDAS, CRP, TCVGH |
| 28 |
2022 |
The effect of exercise training programs with aerobic components on C-reactive protein, erythrocyte sedimentation rate and self-assessed disease activity in people with ankylosing spondylitis: A systematic review and meta-analysis. |
WMD |
| 29 |
2022 |
The relationship between central sensitization and disease activity, quality of life, and sleep quality among patients with axial spondyloarthritis. |
ASDAS-CRP, axSpA, CS, CSI, HC, MASES, PSQI, QoL, SF-36, VAS |
| 30 |
2022 |
The Relationship between Plasma Pentraxin 3 and Serum Amyloid P Levels and Disease Activity in Ankylosing Spondylitis. |
AS, ASDAS, CRP, ESR, PTX3, SAP |
| 31 |
2022 |
The value of SPARCC sacroiliac MRI scoring in axial psoriatic arthritis and its association with other disease parameters. |
ASDAS, axPsA, CRP, DAPSA, MDA, MRI, SIJ, SIS, SPARCC |
| 32 |
2022 |
Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen-B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. |
bDMARDs, HLA-B27, PsA, tsDMARDs |
| 33 |
2022 |
Treatment with Tumour Necrosis Factor Inhibitors is Associated with a Time-Shifted Retardation of Radiographic Sacroiliitis Progression in Patients with Axial Spondyloarthritis: 10-year Results from the German Spondyloarthritis Inception Cohort. |
axSpA, CRP, NSAIDs, TNFi |
| 34 |
2022 |
Upregulated lncRNA-NEF predicts recurrence and poor treatment outcomes of ankylosing spondylitis. |
AS, ASDAS, ESR, HFLS |
| 35 |
2022 |
Validity and psychometric characteristics of the self-administered comorbidity questionnaire in patients with psoriatic arthritis. |
BMI, DAPSA, HAQ, PASI, PsA, PsAQoL, SCQ, SF-36 |
| 36 |
2022 |
Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry. |
ASDAS-CRP, axSpA, BASMI, MASES |
| 37 |
2022 |
Which Metrological Index-the BASMI or EDASMI-is Best Correlated With Disease-Related Parameters in Spondylarthritis Patients? |
ASDAS, ASQoL, axSpA, BASFI, BASMI, BASRI, EDASMI, mSASSS |
| 38 |
2022 |
Worse scores but similar patterns of disease activity: interpreting outcomes in women with axial spondyloarthropathy. |
ASQoL, ASRI, axSpA |
| 39 |
2022 |
[Midterm follow-up outcomes of total hip arthroplasty in treatment for patients with juvenile-onset ankylosing spondylitis]. |
BASFI, HHS, JAS, MCS, PCS, THA |
| 40 |
2022 |
[Therapeutic effects of complex multimodal rheumatologic treatment in the Rheumatology Center, Rhineland-Palatinate]. |
AS, BASFI, CMRT, DA, DAS28, PsA, RA, RA, RA, VAS |
| 41 |
2021 |
Adalimumab and sulfasalazine in alleviating sacroiliac and aortic inflammation detected in PET/CT in patients with axial spondyloarthritis: PETSPA. |
ADA, axSpA, PET/CT, SI, SSZ |
| 42 |
2021 |
Alexithymia in ankylosing spondylitis. |
AS, ASQoL, BASFI, BASMI, BDI, TAS |
| 43 |
2021 |
Angiotensin-Receptor Blockade Improves Inflammation and Endothelial Dysfunction in Ankylosing Spondylitis: ARB-AS Study. |
ARBs, AS, ASDAS, BASFI, CRP, CV, EPCs, ESR, FMD, HAQ-DI, ICAM-1, IL-1, QoL, SCORE, TBARS, TNF-alpha, VCAM-1 |
| 44 |
2021 |
Assessment of hip involvement in patients with ankylosing spondylitis: reliability and validity of the Hip Inflammation MRI Scoring System. |
AS, ASDAS, BASFI, BASRI-hip, CRP, HHS, HIMRISS, ICCs |
| 45 |
2021 |
Assessment of plasma microRNA potentials as a non-invasive biomarker in patients with axial spondyloarthropathy. |
ASAS, miRNAs, qRT-PCR, rad-AxSpA |
| 46 |
2021 |
Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases: Results of the Cardiovascular in Rheumatology (Carma) Project. |
AS, BMI, CARMA, CIRD, DAS28, PsA, RA |
| 47 |
2021 |
Circular RNAs in peripheral blood mononuclear cells from ankylosing spondylitis. |
ALB, AS, ASA, AUC, circRNA, FC, GLOB, HC, hs-CRP, LY, mRNA, ncRNA, PBMCs, PLT, ROC, RT-qPCR |
| 48 |
2021 |
Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs. |
bDMARD, csDMARD, DMARDs, PsA, PsAQoL, QoL |
| 49 |
2021 |
Comparison of the effects of aerobic training alone versus aerobic training combined with clinical Pilates exercises on the functional and psychosocial status of patients with ankylosing spondylitis: A randomized controlled trial. |
6MWT, AS, ASQoL, BASFI, BASMI, BST, CPE, HADS, MAF, PSQI, TSK |
| 50 |
2021 |
Construct Validity of the Routine Assessment of Patient Index Data 3 (RAPID3) in the Evaluation of Axial Spondyloarthritis. |
ASDAS, axSpA, BASFI, mSASSS, RAPID3, ROC |
| 51 |
2021 |
Correlation between C-Reactive Protein to Albumin Ratio and Disease Activity in Patients with Axial Spondyloarthritis. |
ALB, AUC, axSpA, BASFI, CRP, ESR, ROC |
| 52 |
2021 |
Could C-Reactive Protein/Albumin Ratio be an Indicator of Activation in Axial Spondyloarthritis? |
axSpA, CRP, ESR, NLR |
| 53 |
2021 |
Differences in stabilometric correlates of pain relief after wearing postural insoles for six weeks between chronic nociceptive and neuropathic foot pain. An open-label pilot study. |
BPI, NPSI, VAS |
| 54 |
2021 |
Early Improvements in Disease Activity Indices Predict Long-Term Clinical Remission Suggested by the Treat-to-Target Strategy in Patients with Ankylosing Spondylitis Receiving TNF-alpha Inhibitor Treatment. |
AS, CI, CRP, GEEs, OR, TNFi |
| 55 |
2021 |
Effectiveness and safety of Chinese herbal formula combined with western medicine for ankylosing spondylitis: A protocol for systematic review and meta-analysis. |
AS, BASFI, BASMI, CHF, CRP, ESR, GRADE, RCTs, ROBIS, SR, TCM |
| 56 |
2021 |
Efficacy and safety of Fengshi Gutong Capsule in patients with active ankylosing spondylitis: A 4-week randomized controlled, double-blinded, double-dummy trial. |
AS, ASDAS-CRP, BASFI, BASMI, FSGTC, PGTA |
| 57 |
2021 |
Efficacy and safety of thalidomide on psychological symptoms and sleep disturbances in the patient with refractory ankylosing spondylitis. |
AS, BASFI, BASMI |
| 58 |
2021 |
Efficacy and Safety of Wenbu Zhibi Granule in Patients with Ankylosing Spondylitis: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. |
AS, ASDAS, ASQoL, BASFI, BASMI, SPARCC, WZG |
| 59 |
2021 |
Heart Involvement in a Moroccan Population with Spondyloarthritis: A Cross-sectional Study. |
AR, ASAS, ASDAS, AVT, BASFI, CVRF, ECG, MR, MS, RBBB, SpA, TTE |
| 60 |
2021 |
HLA-B27 is associated with reduced disease activity in axial spondyloarthritis. |
axSpA, SpA |
| 61 |
2021 |
Impact of axial spondyloarthritis on mental health in Europe: results from the EMAS study. |
axSpA |
| 62 |
2021 |
Impact of obesity on quality of life, psychological status, and disease activity in psoriatic arthritis: a multi‑center study. |
BMI, DAPSA, DAS28-CRP, FACIT, HADS, HAQ, HAQ-S, PASI, PsA, PsAQoL, VAS-F, VAS-P |
| 63 |
2021 |
Influence of anti-TNF-α treatment on liver and kidney functions in patients with ankylosing spondylitis: A retrospective longitudinal study. |
AS, AST, CRP, ESR, TNF-alpha |
| 64 |
2021 |
Is There a Correlation Between Patient-Reported Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score and MRI Findings in Axial Spondyloarthropathy in Routine Clinical Practice? |
axSpA, MRI, PRO |
| 65 |
2021 |
Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results. |
ASAS, bDMARD, r-axSpA, TNFi |
| 66 |
2021 |
Long noncoding RNA intersectin 1-2 gradually declines during adalimumab treatment, and its reduction correlates with treatment efficacy in patients with ankylosing spondylitis. |
AS, ASAS, ASDASCRP, CRP, IL, lnc-ITSN1-2, PBMC, TNF-alpha |
| 67 |
2021 |
Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study. |
AS, ASDAS, CRP, TNF |
| 68 |
2021 |
Medication adherence and persistence of psoriatic arthritis patients treated with biological therapy in a specialty pharmacy in Brazil: a prospective observational study. |
PsA |
| 69 |
2021 |
miRNA-451a and miRNA-125a Expression Levels in Ankylosing Spondylitis: Impact on Disease Diagnosis, Prognosis, and Outcomes. |
AS, AUC, miRNAs |
| 70 |
2021 |
Patient Perspectives on Biologics for Axial Spondyloarthritis in a Cross-sectional Study in a Predominantly Female Population: Treatment Satisfaction, Wear-off Between Doses, and Use of Supplemental Medication. |
bDMARDs, SD |
| 71 |
2021 |
Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis. |
ASDAS-CRP, axSpA, CI, CV |
| 72 |
2021 |
Predictors of Health-Related Quality of Life in Patients with Ankylosing Spondylitis in Southwest China. |
AS, BAS-G, BASFI, BDI-II, MCS, PCS, QoL |
| 73 |
2021 |
Prevalence of Temporomandibular Joint Disorders in Patients with Ankylosing Spondylitis: A Cross-Sectional Study. |
AS, BASFI, HAQ-S, TMD |
| 74 |
2021 |
Procollagen I N-terminal peptide correlates with inflammation on sacroiliac joint magnetic resonance imaging in ankylosing spondylitis but not in non-radiographic axial spondyloarthritis: A cross-sectional study. |
AS, ASDAS, BASFI, CRP, ESR, MRI, nr-axSpA, OC, PINP, SIJ, SPARCC |
| 75 |
2021 |
Relationship between periodontal status and disease activity in patients with ankylosing spondylitis. |
AS, ASQoL, BASFI, BASMI, GI, MASES, NSAID, PD, PI, TNF |
| 76 |
2021 |
Reviewing Disease Activity Indices in Spondyloarthritis From the Sex Perspective: A Systematic Review and Metaanalysis. |
ASDAS, SpA |
| 77 |
2021 |
Rheumatoid arthritis coexisting with ankylosing spondylitis: A report of 22 cases with delayed diagnosis. |
AS, DAS28, RA, RA/AS |
| 78 |
2021 |
Serum IL-6 and TNF-α Levels Are Correlated with Disease Severity in Patients with Ankylosing Spondylitis. |
AS, CT, HCs, IL, TNF-alpha |
| 79 |
2021 |
Serum RANKL levels in Chinese patients with ankylosing spondylitis: a meta-analysis. |
AS, BASFI, OPG, SMD, SMDs, sRANKL |
| 80 |
2021 |
Structural Lesion Progression of the Sacroiliac Joint and Clinical Features in axSpA During TNFi Reduction: A Retrospective Cohort Study. |
ASDAS, axSpA, BASFI, DQ, SIJ, SPARCC, TNFi |
| 81 |
2021 |
Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial. |
ASDAS, ASQoL, BASFI, re |
| 82 |
2021 |
SWE and SMI ultrasound techniques for monitoring needling treatment of ankylosing spondylitis: study protocol for a single-blinded randomized controlled trial. |
AS, ASQoL, BASFI, BASMI, CSA, FS-14, QoL, SIJ, SMI, SWE, VAS |
| 83 |
2021 |
Systemic immune-inflammation index is associated with disease activity in patients with ankylosing spondylitis. |
AS, CRP, ESR, SII |
| 84 |
2021 |
The association between elevated serum interleukin-22 and the clinical diagnosis of axial spondyloarthritis: A retrospective study. |
ASDAS, axSpA, IL-22, mSASSS |
| 85 |
2021 |
The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study. |
ASDAS, BME, CRP, ESR, HIMRISS, SpA, TNF |
| 86 |
2021 |
The Delay of Diagnosis in Spondyloarthropathy Patients in a Tertiary Hospital in Saudi Arabia. |
AS, ASDAS, CRP, DD, EnA, IBD, PsA, SpA |
| 87 |
2021 |
The effect of Pulmonary Rehabilitation Programme on work productivity and clinical parameters in patients with ankylosing spondylitis. |
6MWT, AS, ASQOL, BASFI, BDS, RFTs |
| 88 |
2021 |
The evaluation of bone marrow edema in sacroiliac joint in patients with ankylosing spondylitis using magnetic resonance imaging Dixon sequence. |
AS, BASFI, CRP, ESR, MRI |
| 89 |
2021 |
The Role of Clinical and Ultrasound Enthesitis Scores in Ankylosing Spondylitis. |
AS, ASDAS, BUSES, SpA, SPARCC |
| 90 |
2021 |
The toll of unemployment in axial spondyloarthropathy: high prevalence and negative impact on outcomes captured in a national registry. |
ASRI, axSpA, HAQ |
| 91 |
2021 |
The Value of Serum Amyloid A in the Diagnosis and Management of Ankylosing Spondylitis. |
AS, CRP, ESR, SAA |
| 92 |
2021 |
Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study. |
axSpA, DAGDO, DAS28-CRP, LDA, TNFi |
| 93 |
2021 |
Use of Quantitative Vertebral Bone Marrow Fat Fraction to Assess Disease Activity and Chronicity in Patients with Ankylosing Spondylitis. |
AS, ASDAS-CRP, BASFI, FF, MRI, mSASSS |
| 94 |
2021 |
Using a novel smartphone application for capturing of patient-reported outcome measures among patients with inflammatory arthritis:A randomized, crossover, agreement study. |
app, CIs, DANBIO, IA, MCID, PROMs |
| 95 |
2021 |
Which factors explain the patient global assessment in patients with ankylosing spondylitis? A hierarchical cluster analysis on REGISPONSER-AS. |
AS, BAS-G, BASFI, MASES |
| 96 |
2021 |
Yisaipu Provide AS Patients With an Economical Therapeutic Option While Original Biologicals are More Advantageous in the COVID-19 Epidemic Situation. |
AS, ASDAS-CRP, HAQ-S, PFS, TNF |
| 97 |
2020 |
Association of body mass index on disease activity in axial spondyloarthritis: systematic review and meta-analysis. |
ASDAS, axSpA, BMI, SMDs |
| 98 |
2020 |
Benefit of Biological Drugs for Quality of Life in Patients with Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of Clinical Trials. |
AS, ASAS, ASQoL, BASFI, FACIT-F, QoL |
| 99 |
2020 |
BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritis. |
axSpA, CI, DAS28, RA, SAEs |
| 100 |
2020 |
Biologic disease-modifying anti-rheumatic drugs and patient-reported outcomes in axial SpA: a systematic review and a call for action. |
ASQoL, axSpA, BASFI, bDMARDs, EQ-5D, FACIT-F, IL17Ai, MCID, nr-axSpA, PBO, PROs, r-axSpA, RCT, SF36-MCS, SF36-PCS, SLR, TNFi |
|
A Search Service for Abbreviation / Long Form
